Loading clinical trials...

Comparison for the Effect of Neuromuscular Blocking Agents Versus Sedation Alone on Severe ARDS Patients Due to COVID-19 | Clinical Trials | Clareo Health

COMPLETEDNA

Comparison for the Effect of Neuromuscular Blocking Agents Versus Sedation Alone on Severe ARDS Patients Due to COVID-19

NCT04922814•Assiut University

View on ClinicalTrials.gov

Summary

Many questions about management of COVID-19 are still not answered. So, we recruit this study aiming to evaluate improvement of oxygenation in COVID-19 patients with severe ARDS, to improve morbidity and mortality of ICU covid patients, to participate in understanding of real hidden pathophysiology of COVID-19.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Severe ARDS: PaO2/FiO2 \<200, resistant hypoxemia and tachypnoea (RR \> 40 breath/minute)
•Not relieved by high frequency nasal canula or CPAP.
•Need for invasive mechanical ventilation (uncooperative)

Exclusion Criteria

•Patient relatives' refusal
•Not mechanically ventilated.
•Combination of female, corticosteroids administration and vecuronium muscle relaxant.
•Neuromuscular diseases (especially demyelinating diseases).

Locations (1)

Assiut university, faculty of medicine, anesthesia and ICU and pain management department

Asyut, Asyut Governorate, Egypt

Key Dates

Start Date

August 1, 2021

Primary Completion Date

March 1, 2022

Completion Date

August 1, 2022

Last Updated

December 24, 2025

Enrollment

ACTUAL participants

Conditions

COVID-19 Acute Respiratory Distress SyndromeSedation ComplicationICU Acquired Weakness

Interventions

muscle relaxation

DRUG

Feasibility and Safety of Digital Rehab Platform for Bedridden Patients

NCT06849765

ICU Acquired Weakness (ICUAW)

View study

RECRUITING

Validation of a Processed EEG Device for Monitoring Sedation in PICU

NCT05969483

Sedation Complication

View study

RECRUITINGNA

Effect of Goal-directed Analgesia and Sedation Using EEG Derived QCON/qNOX in ICU Patients

NCT06769308

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 24, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Comparison for the Effect of Neuromuscular Blocking Agents Versus Sedation Alone on Severe ARDS Patients Due to COVID-19

Inclusion Criteria

Exclusion Criteria

Feasibility and Safety of Digital Rehab Platform for Bedridden Patients

Validation of a Processed EEG Device for Monitoring Sedation in PICU

Effect of Goal-directed Analgesia and Sedation Using EEG Derived QCON/qNOX in ICU Patients

Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®

Closed Loop Acoustic Stimulation During Sedation With Dexmedetomidine

Effect of Protein, Mobility Therapy and Electric Stimulation on Recovery in Older ICU Survivors